Hemorrhagic Syndrome in Dogs Induced by Intravenous Thrombin

Summary

The intravenous administration of thrombin (70 N. I. H. u/kg) caused in the dog a decrease in platelets, factor V, factor VIII and fibrinogen, a prolongation of glass and silicone clotting times, prothrombin and partial thromboplastin times, decreased prothrombin consumption and defective thromboplastin generation. This resulted in a generalized bleeding syndrome. Increased fibrinolysis occurred after an initial phase of inhibition of fibrinolysis. It is suggested that this hemorrhagic syndrome is similar to some conditions observed clinically.

^* Visiting Research Fellow, Sloan-Kettering Institute for Cancer Research. Permanent Address: Institute of “Semeiotica Medica” (Head: Prof. M. Austoni), University of Padua Medical School, Padua, Italy.

^** Associate Member, Sloan-Kettering Institute for Cancer Research.

^*** Research Associate, Sloan-Kettering Institute for Cancer Research.

• References

• 1 Page E. W, Fulton L. D, Glendening M. B. Cause of blood coagulation defect following abruptio placentae., Amer. J. Obstet. Gynec 61: 1116 1951;
• 2 Albrechtsen O. K, Storm O, Trolle D. Fibrinolytic activity in the circulating blood following amniotic fluid infusion. Actahaemat. (Basel) 14: 309 1955;
• 3 Reid D. E, Weiner A. E, Roby C.C. Intravascular clotting and afibrinogenemia, presumptive lethal factors in the syndrome of amniotic fluid embolism. Amer. J. Obstet. Gynec 66: 465 1953;
• 4 Merskey C, Johnson A. J, Pert J. M, Wohl M. Pathogenesis of fibrinolysis in defibrination syndrome: Effect of heparin administration. Blood 24: 701 1964;
• 5 Soulier J. P, Mathey J, LeBolloch A. G, Daumet Ph, Fayet H. Syndromes hémorragiques mortels avec incoagulabilité totale par defibrination et avec fibrinolyse. 1. Au cours des exérèses pulmonaires. Rev. Hémat 7: 30 1952;
• 6 Tagnon H. J, Levenson S. M, Davidson C. D, Taylor F. H. L. The occurrence of fibrinolysis in shock with observations on the prothrombin time and the plasma fibrinogen during hemorrhagic shock. Amer. J. med. Sci 211: 88 1946;
• 7 Cooperberg A. A, Neiman G. M. A. Fibrinogenopenia and fibrinolysis in acute myelogenous leukemia. Ann. intern. Med 42: 706 1955;
• 8 Baker W. G, Bang N. U, Nachman R. L, Roofat F, Horowitz H. I. Hypofibrinogenemic hemorrhage in acute myelogenous leukemia treated with heparin. Ann. intern. Med 61: 116 1964;
• 9 Stefanini M, Giammalvo J. T, Karaca M. Demonstration of two additional mechanisms in the pathogenesis of the syndrome of acquired fibrinogenopenia. Ann. J. med. Sci 246: 58 1963;
• 10 Schneider G. L. Mechanisms of production of acute fibrinogen deficiencies. Progress in Hematology 1:202 (1956) Tocantis L. M. ed. Gruñe & Stratton; New York and London: 1956
• 11 Scott E. V. Z, Mathews W. F, Butterworth Jr. G. E, Frommeyer Jr. W. B. Abnormal plasma proteolytic activity. Diagnosis and treatment. Surg. Gynec. Obstet 99: 679 1954;
• 12 Moloney W. G, Egan W. J, Gorman A. J. Acquired afibrinogenemia in pregnancy. New Engl. J. Med 240: 596 1949;
• 13 Allen J. G, Glotzer D. J. Acute disseminated intravascular coagulation and fibrinolysis. Arch. Surg SS: 694 1964;
• 14 Astrup T, Volkert M. On the action of thrombin and thrombokinase in vivo. Acta med. scand 115: 393 1934;
• 15 Brayton R. G, Zucker M. B. Bleeding syndrome in thrombin injected rats deficient in fibrinogen and antihemophilic factor. Proc. Soc. exp. Biol. (N. Y.) 96: 418 1957;
• 16 Ratnoff O. D, Conley G. L. Studies in afibrinogenemia. II. Defibrinating effect on dog plasma of intravenous injection of thromboplastic material. Bull. Johns Hopk. Hosp 88: 414 1951;
• 17 Nolf P, Adant M. La defibrination “in vivo” par injection intraveineuse de thrombine chez le chien normal ou hepatectomisé. Sang 25: 193 1954;
• 18 Quick A. J, Hussey G. V, Harris J, Peters K. Occult intravascular clotting by means of intravenous injection of thrombin. Amer. J. Physiol 197: 791 1959;
• 19 Tagnon H. The nature of the mechanism of shock produced by the injection of trypsin and thrombin. J. clin. Invest 24: 1 1945;
• 20 Warner E. D, Brinkhous K. M, Seegers W. H, Smith H. P. Further experience with the use of thrombin as a hemostatic agent. Proc. Soc. exp. Biol. (N. Y.) 41: 655 1939;
• 21 Hardaway R. M, Watson H, Weis F. N. Alterations of blood coagulation mechanism after intra-aorta injection of thrombin. Arch. Surg 81: 983 1960;
• 22 Lee R. I, White P. D. A clinical study of the coagulation time of blood. Amer. J. med. Sci 245: 495 1913;
• 23 Quick A. J. The physiology and pathology of hemostasis. Lea and Febiger; Phila.: 1951
• 24 Lewis J. H, Ferguson J. H, Fresh J. W, Zucker M. B. Primary hemorrhagic diseases. J. Lab. clin. Med 49: 211 1957;
• 25 Hardisty R. M, MacPherson J. C. A one-stage Factor VIII (antihemophilic Globulin) Assay and its use on venous and capillary plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 7: 215 1962;
• 26 Langdell R. D, Wagner R. M, Brinkhous K. M. Effect of antihemophilic factor on the one-stage clotting tests. A presumptive test for hemophilia and a simple one-stage antihemophilic factor assay procedure. J. Lab. clin. Med 41: 637 1953;
• 27 Mootse G, Agostino D, Clijfton E. E. Alterations in Fibrinogen, Plasminogen and Inhibitors of Plasmin with the growth of V2 Carcinoma in Rabbits. J. nat. Cancer. Inst 35: 567 1965;
• 28 Cliffton E. E, Cannamela D. A. Fibrinolytic and proteolytic activity of human plasminogen prepared from fraction III of human plasma. J. appl. Physiol 6: 42 1953;
• 29 Downie G. R, Clijfton E. E. A method for assay of serum proteolytic activity. Proc. Soc. exp. Biol. (N. Y.) 71: 138 1949;
• 30 Proctor R. R, Rappaport S. I. The partial thromboplastin time with kaolin. Amer. J. clin. Path 36: 212 1961;
• 31 Hicks N. D, Pitney W. R. A rapid screening test for disorders of thromboplastin generation. Brit. J. Hemat 3: 237 1957;
• 32 Coon W. A, Duff I. V. Effect of intravenous human plasmin on the blood clotting mechanism of the dog. J. Lab. clin. Med 51: 381 1958;
• 33 Sherry S, Fletcher A. P, Alkjaersig N. Fibrinolysis and fibrinolytic activity in man. Physiol. Rev 39: 343 1959;
• 34 Fletcher A. P, Alkjaersig N, Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (fibrinolytic) states. I. J. clin. Invest 41: 896 1962;
• 35 Niewiarowski S, Latallo Z. Influence of plasmin on the first coagulation stage. Bull. Acad, poi. Sci. Cf. 2 5: 219 1957;
• 36 Soulier J. P, Alagille D, Larrieu M. J. Modifications “in vivo” des facteurs de coagulation dans les fibrinolyses. Valeur du déficit en proaccélérine pour le diagnostic des proteolyses frustes ou latentes. Sem. Hôp. Paris 32: 359 1956;
• 37 Donaldson V. H. Effect of plasmin in vitro on the clotting factors in plasma. J. Lab. clin. Med 50: 644 1960;
• 38 Ware A. G, Murphy E. G, Seegers W. H. The function of Ac-Globulin in blood clotting. Science 106: 618 1947;
• 39 Murphy R. G, Ware A. G, Seegers W. H. Stability of serum Ac-Globulin. Proc. Soc. exp. Biol. (N. Y.) 69: 216 1948;
• 40 Siegel M, Cliffton E. E. The role of a contaminant in thrombin in the human plasmin system. J. Gen. Physiol 40: 377 1953;
• 41 Penick G. D. Antihemophilic factor (AHF): Its inactivation in relation to thrombin evolution. Fed. Proc 16: 369 1957;
• 42 O’Brien J. B. A comparison of platelet aggregation produced by seven compounds and a comparison of their inhibitors. J. clin. Path 17: 275 1964;
• 43 Batallo Z. S, Fletcher A. P, Alkjaersig N, Sherry S. Inhibition of fibrin polymerization by fibrinogen proteolysis products. Amer. J. Phys 202: 681 1962;
• 44 Kowalski E, Budzynski A. Z, Kopec M, Batallo Z. S, Lipinski B, Wegrzynowicz Z. Studies on the molecular pathology and pathogenesis of bleeding in severe fibrinolytic states in dogs. Thrombos. Diathes. haemorrh. (Stuttg.) 12: 69 1964;
• 45 Kowalski E, Budzynski A. Z, Kopec M, Batallo Z. S, Lipinski B, Wegrzynowicz Z. Circulating fibrinogen degradation products (FDP) in dog blood after intravenous thrombin infusion. Thrombos. Diathes. haemorrh. (Stuttg.) 13: 12 1965;